Key Stats for Zoetis Stock
- Past-Week Performance: +0.04%
- 52-Week Range: $114.4 to $172.2
- Current Price: $115.7
What Happened?
Zoetis (ZTS), the world’s largest animal health company, enters 2026 trading near its 52-week low of $114.36 while guiding to adjusted EPS of $7.00 to $7.10, a figure that topped Wall Street’s $6.80 consensus despite shares sitting 33% below their 52-week high of $172.23.
On March 2, Zoetis agreed to acquire Neogen’s animal genomics business, which uses genetic testing to predict and tailor individual animal health outcomes, for $160 million, closing expected in the second half of 2026, as the company simultaneously reported Q4 adjusted EPS of $1.48, beating the $1.40 consensus.
Simparica Trio, the company’s triple-combination parasite prevention pill for dogs and its first U.S. brand to cross $1 billion in annual sales, grew 13% operationally in 2025 while triple-combination products now hold 50% of U.S. clinic patient share, up from roughly 25% two years ago, with puppies already at two-thirds adoption signaling further runway.
CFO Wetteny Joseph stated at the Barclays 28th Annual Global Healthcare Conference on March 10 that “our international companion animal business has grown at a very similar rate to the U.S. companion animal business,” underscoring how the international segment’s 8% organic operational growth in 2025 offsets near-term U.S. clinic softness tied to price-sensitive millennial and Gen Z pet owners.
Zoetis enters its most consequential product cycle in years, with long-acting OA pain drug Lenivia launching in the EU and Canada in the first half of 2026, U.S. approval for a renal disease treatment targeting a $3 billion to $4 billion market expected in 2027, 12 potential blockbusters in the pipeline, and roughly $2.4 billion remaining on its buyback authorization to support per-share value as the new product cycle matures.
Wall Street’s Take on ZTS Stock
The Neogen acquisition and Lenivia launch confirm that Zoetis is spending its way into the next growth cycle precisely when the market has priced it as a business in retreat, with shares down 33% from their 52-week high even as 2026 free cash flow, the cash a company generates after all capital expenditures, is estimated to jump 21.6% to $2.78 billion.
That FCF expansion from $2.28 billion in 2025 to $2.78 billion in 2026 is not a projection built on hope: it reflects Simparica Trio’s continued penetration of a U.S. triple-combination parasiticide market that has grown from 25% to 50% clinic share in two years, normalized pricing of 2% to 3%, and Librela stabilization already confirmed in Q4 2025 trends.
ZTS’ normalized EPS is estimated to reach $7.03 in 2026 and $7.54 in 2027, compounding at a 6.9% CAGR through 2030 per the TIKR model’s mid-case, while FCF margins expand from 24.1% in 2025 to 29.8% by 2027, a trajectory that peer Elanco Animal Health, still working through its own integration challenges, is nowhere near replicating.
Wall Street sits at 7 buys, 4 outperforms, and 9 holds as of March 20, with a mean price target of $151.00 implying 30.5% upside from $115.67, a consensus that reflects near-term caution on U.S. clinic traffic but does not yet fully account for the renal franchise targeting a $3 billion to $4 billion market entering approval in 2027.
The spread between the $130.00 analyst floor and the $190.00 ceiling tells the story plainly: the low target assumes Librela’s U.S. decline accelerates and dermatology competition structurally erodes share, while the high target prices in the renal approval cycle and continued Simparica Trio penetration past 50% clinic share toward the two-thirds puppy-adoption rate already visible in the data.
What Does the Valuation Model Say?
The TIKR mid-case target of $170.45, implying a 47.4% total return and 8.4% annualized IRR through December 2030, is built on a 5.1% revenue CAGR and a net income margin expanding from 29.1% to 30.9%, a reasonable assumption given that livestock, diagnostics, and international companion animal together generated 8%, 13%, and 7% operational growth respectively in 2025 with no signs of structural deterioration.
The market is pricing ZTS as a U.S. clinic story in decline; the TIKR model prices it as a global, multi-franchise compounder, and the 2025 international segment alone, growing 8% organically, already offsets the headline U.S. softness.
The $2.4 billion remaining buyback authorization, combined with $2.78 billion in estimated 2026 FCF, signals that management has both the capital and the conviction to buy shares at prices the TIKR model identifies as a 47% discount to fair value.
If Librela’s U.S. trajectory does not stabilize through the first half of 2026, the OA pain franchise’s assumed return to growth breaks the EBITDA margin expansion embedded in the $170.45 target, and the model’s mid-case collapses toward the $139.38 low case.
Q1 2026 earnings, the first report under the new fiscal-year calendar alignment, will confirm whether Simparica Trio’s U.S. growth is reaccelerating and whether Librela’s stabilization held through the competitive launch window: watch for U.S. companion animal organic operational growth above flat and Librela sequential revenue above $36 million.
Should You Invest in Zoetis Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ZTS stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Zoetis Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ZTS stock on TIKR for Free →
